Bayer AG’s betaferon multiple sclerosis treatment helped patients live longer when taken soon after the onset of the disease in a study researchers said is the first to show such a drug extends ...

Schering AG of Germany – a unit of Bayer – has been granted approval in Australia to market its multiple sclerosis drug Betaferon for patients in the early stages of the disease. Schering AG of ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to speak ...

Berlin, December 1, 2009 - Bayer Schering Pharma AG announced today that the Chinese State Food and Drug Administration (SFDA) has approved Betaferon® (interferon beta-1b) therapy for patients with ...

CAMBRIDGE, MA – Sept. 11, 2009 – Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...

Bayer has exercised its option under an agreement with US biotechnology company Micromet to develop a new antibody for the treatment of solid tumours. Bayer has exercised its option under an agreement ...

FRANKFURT, Oct 29 (Reuters) - Bayer will take a 152 million-euro ($218 million) impairment charge after its higher dose multiple-sclerosis drug Betaferon failed to show it could work better than the ...

CAMBRIDGE, Mass.-(BUSINESS WIRE) - Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis (MS) patients taking AVONEX (interferon ...

FRANKFURT (Reuters) - Bayer's multiple sclerosis (MS) treatment Betaferon was shown to be more effective when given on the first sign of the disease than if treatment is delayed, the German drugmaker ...

BERLIN German drug maker Bayer HealthCare said a 16-year follow-up to a clinical trial of one of its multiple sclerosis drugs supported the drug’s safety record. Bayer said results of the follow-up ...

You win some, you lose some. Bayer is abandoning plans to launch a bigger dose of its multiple sclerosis treatment Betaferon. An internal study found that the 500 mcg dose wasn't any more effective ...

The Business Research Company's Betaferon Or Betaseron Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...